Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

ABU DHABI, 25th February, 2026 (WAM) -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has published the Guideline for Management of Multiple ...

A Senate committee approved a bill expanding medical marijuana eligibility on Tuesday and voted down another allowing it in hospitals on Wednesday.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of ...

Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.

Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life.

Two large real-world analyses presented at ACTRIMS Forum 2026 shed new light on the multiple sclerosis (MS) care continuum, ...

It’s a sign of just how much attitudes about the patches, and about menopause, have changed. After a report in 2002 suggested that hormone therapy increased the risks of breast cancer and ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approxima ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...